What is it about?
The cardiovascular (CV) safety of glucagon-like peptide 1 (GLP-1) receptor agonists has been established in robust cardiovascular outcomes trials in patients with type 2 diabetes at high CV risk but which drugs have demonstrated a significant CV benefit.
Featured Image
Photo by Ali Hajiluyi on Unsplash
Why is it important?
Guidelines for the treatment of type 2 diabetes have evolved from a glucocentric focus to one that now focuses on reducing overall CV risk by personalizing therapy and using drugs such as GLP-1 receptor agonists with proven CV benefits
Read the Original
This page is a summary of: Cardiovascular Outcomes Trials of Incretin-Based Therapies, Diabetes Spectrum, August 2021, American Diabetes Association,
DOI: 10.2337/ds20-0072.
You can read the full text:
Contributors
The following have contributed to this page
